Category: 170097-67-3

170097-67-3,170097-67-3, 2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Intermediate 9: 1 ,1-dimethylethyl 6-({ri-({5-chloro-2-r(2-methylpropyl)oxylphenyl}methyl)-5- ethyl-I H-pyrazol-S-yliaminolcarbonvD-S^-dihydro^d l-D-isoquinolinecarboxylate; To a solution of 1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-ethyl-1 H-pyrazol-3- amine (Intermediate 7) (0.5 g, 1.62 mmol) in DMF (1 OmL) was added 2-{[(1 ,1- dimethylethyOoxylcarbonylJ-I ^.S^-tetrahydro-theta-isoquinolinecarboxylic acid (0.41 g, 0.9 eq.), HATU (0.74 g, 1.2 eq.) and DIEA (0.34 ml_,1.2 eq.) and the mixture was stirred at room temperature for 24 hours. The solvent was evaporated under reduced pressure and the residue was diluted with DCM. The organic phase was then washed with water and dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by flash column chromatography eluting with DCM/EtOAc: 95/5 to give the title compound as an oil (120 mg, 13%). LC/MS: m/z 567 (M+H)+ Rt: 4.23 min.

170097-67-3,2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acidbelongs to tetrahydroisoquinoline compound, is more and more widely used in various fields. and we look forward to future research findings.

Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2008/74834; (2008); A2;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

170097-67-3, 2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

2-(tert-Butoxycarbonyl)- 1,2,3 ,4-tetrahydroisoquinoline-6-carboxylic acid (100 mg, 0.361 mmol) was dissolved in THF (5 mL) in an oven dried flask at -78 C. TMEDA (0.174 mL, 1.15 mmol) was added, followed by dropwise addition of a 1.6 M solution of n-BuLi in hexane (0.721 mL, 1.15 mmol) over 1 mm. The reaction mixture was stirred at-78 C for 1 hour, then a solution of Mel (0.090 mL, 1.4 mmol) dissolved in 1 mL of THFwas added. The reaction was allowed to warm to rt, and stirring was continued at rt for 45minutes. The reaction was then quenched with an aq. solution of saturated NH4C1 and extracted 3x with EtOAc. The combined organic extracts were dried with Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography to provide 181A(70 mg, 67% yield), as a white solid. MS(ESI)m/z 290.1 (M-H)., 170097-67-3

As the paragraph descriping shows that 170097-67-3 is playing an increasingly important role.

Reference£º
Patent; BRISTOL-MYERS SQUIBB COMPANY; SMALLHEER, Joanne, M.; SHAW, Scott, A.; HALPERN, Oz, Scott; HU, Carol, Hui; KICK, Ellen, K.; (311 pag.)WO2017/40449; (2017); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

170097-67-3, 2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of 2-{[(1 ,1-dimethylethyl)oxy]carbonyl}-1 ,2,3,4-tetrahydro-6- isoquinolinecarboxylic acid (555 mg, 2 mmol), HATU (989 mg, 2.6 mmol), triethylamine (0.26 ml_, 2.6mmol) in DMF (15 ml.) and 5-{[(2-chlorophenyl)(methyl)amino]methyl}- 1 ,3,4-thiadiazol-2-amine (Intermediate 240) (509 mg, 2 mmol) was stirred at room temperature overnight. The DMF was evaporated under reduced pressure and the residue was dissolved in DCM. The organic phase was dried over sodium sulphate, filtered and evaporated under reduced pressure. The residue was purified by flash column chromatography eluting with a gradient DCM 100% to DCM/MeOH: 98/2. After evaporation of the right fractions, the material was triturated in hot methyl alcohol, to give after filtration and drying the title compound as a white solid (300 mg, 29%). HRMS calculated for C25H28CIN5O3S (M+H)+ 514.1680, found: 514.1651, Rt: 3.47 min.

170097-67-3, As the paragraph descriping shows that 170097-67-3 is playing an increasingly important role.

Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2008/104524; (2008); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

170097-67-3, 2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step 3: lambda/-({2-r(trifluoromethvnoxylphenyl}methylV1 ,2.3.4-tetrahvdro-6- isoquinolinecarboxamide; To a solution of aforementioned carboxylic acid (0.20 g, 0.72 mmol) in DMF (5 ml.) was added DMAP (24.0 mg, 0.22 mmol) followed by 2-(trifluoromethoxy)benzylamine (108 DL, 0.79 mmol) and EDCI (138 mg, 0.72 mmol). After stirring overnight, the reaction was poured into H2O (10 ml.) and extracted with EtOAc (2×10 ml_). The organics were dried (Na2SO4) and evacuated. The crude material was redissolved in CH2CI2 (2 ml.) and treated with TFA (2 ml_). After stirring for 30 minutes, the reaction was diluted with CH2CI2 (15 ml.) and poured into ice cold 1 N NaOH (20 ml_). The organics were extracted, dried (Na2SO4), and evacuated to afford the title compound (0.15 g, 59%), which was used without further purification. MS (ES+) m/e 335.0 [M+1]+, 170097-67-3

The synthetic route of 170097-67-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2009/49154; (2009); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

170097-67-3,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170097-67-3,2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid,as a common compound, the synthetic route is as follows.

Intermediate 13: 1 ,1-Dimethylethyl 6-({ri-(1-naphthalenylmethyl)-1 /-/-pyrazol-4- vHamino)carbonyl)-3,4-dihvdro-2(1 H)-isoquinolinecarboxylate; To a solution of 2-{[(1 ,1-dimethylethyl)oxy]carbonyl}-1 ,2,3,4-tetrahydro-6-isoquinoline carboxylic acid (138 mg, 0.5 mmol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (114 mg, 0.6 mmol), 1-hydroxybenzotriazole hydrate (81 mg, 0.6 mmol) and triethylamine (60 mg, 0.6 mmol) in DCM (10 ml.) was added 1-(1- naphthalenylmethyl)-1 H-pyrazol-4-amine (11 1 mg, 0.5 mmol) and the reaction mixture was stirred at room temperature overnight. The organic phase was diluted with an additional volume of DCM then washed with a saturated sodium hydrogeno carbonate solution, with brine, dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by flash column chromatography eluting with DCM/MeOH: 97/3 to give the title compound as an orange oil (180 mg, 81%). LC/MS: m/z 483 (M+H)+, Rt: 3.53 min.

170097-67-3,2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acidbelongs to tetrahydroisoquinoline compound, is more and more widely used in various fields. and we look forward to future research findings.

Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2008/74824; (2008); A2;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170097-67-3,2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid,as a common compound, the synthetic route is as follows.

A solution of 2-{[(1 ,1-dimethylethyl)oxy]carbonyl}-1 ,2,3,4-tetrahydro-6- isoquinolinecarboxylic acid (14.3 g, 52 mmol), HATU (29.5 g, 77.6 mmol), DIPEA (14.6 ml_, 62 mmol) in DMF was stirred at room temperature for 1 hour. 5-{[(2- chlorophenyl)oxy]methyl}-1 ,3,4-thiadiazol-2-amine, (Intermediate 95) (15 g, 62 mmol) was added and the mixture was stirred at room temperature overnight. The DMF was evaporated under reduced pressure and the residue was dissolved in EtOAc. The organic phase was then washed with water and filtered to eliminate an insoluble. The aqueous phase was re-extracted with EtOAc, and the organic phase was dried over sodium sulphate, filtered and evaporated under reduced pressure. The residue was then diluted with DCM and the insoluble was filtered. All the organic phases were combined, dried over sodium sulphate, filtered and evaporated under reduced pressure to give the title compound (14 g, 62%).1H NMR (300 MHz, DMSO, ppm) delta: 7.96 (s, 1 H), 7.93 (d, 1 H), 7.48 (d, 1 H), 7.36 (m, 3H), 7.04 (m, 1 H), 5.64 (s, 2H), 4.59 (s, 2H), 3.60 (t, 2H), 2.86 (t, 2H), 1.44 (s, 9H)., 170097-67-3

The synthetic route of 170097-67-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2008/104524; (2008); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170097-67-3,2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid,as a common compound, the synthetic route is as follows.

To a stirred solution of 1 (1.5 g, 5.4 mmol) in toluene (15 mL) was added DPPA (2.17 g, 8.11 mmol), Et3N (1.05 mL, 8.11 mmol) and benzyl alcohol (0.876 g, 8.11 mmol) under N2. The reaction mixture was allowed to reflux for 12 h, cooled and diluted with ethyl acetate (100 mL). It was washed with water (5 mL), brine solution (5 mL) and dried over Na2SO4. It was filtered and concentrated under reduced pressure and the residue was purified by column chromatography (SiO2, 60-120, chloroform/methanol, 9/1) gave 2 (2.0 g, 97%) as a white solid.

170097-67-3, As the paragraph descriping shows that 170097-67-3 is playing an increasingly important role.

Reference£º
Patent; AVILA THERAPEUTICS AND USES THEREOF; WO2009/158571; (2009); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

170097-67-3, 2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of 2-[(2-methylpropan-2-yl)oxycarbonyl]-3,4-dihydro-lH-isoquinoline-6- carboxylic acid (CAS-RN 170097-67-3; 300 mg, 1.08 mmol) in N,N-dimethylformamide (5 ml) was added 4-methylmorpholine (547 mg, 5.41 mmol), 4,5,6,7-tetrahydro-lH-[l,2,3]triazolo[4,5- c]pyridine (CAS-RN 706757-05-3; 141 mg, 1.08 mmol) and 0-(7-azabenzotriazol-l-yl)- Nu,Nu,Nu’,Nu’-tetramethyluronium hexafluoro-phosphate (411 mg, 1.08 mmol) at room temperature, then after 18 h the reaction mixture was partitioned between sat. aq. sodium hydrogen carbonate solution and a mixture of ethyl acetate and 2-methyltetrahydrofuran. The organic layer was washed with ammonium chloride solution and brine, dried over magnesium sulfate, filtered and evaporated. Chromatography (silica gel, gradient dichloromethane to dichloromethane / methanol / 25% aq. ammonia solution 90 : 10 : 2.5) produced the title compound (278 mg, 67%). White foam, MS: 384.3 (M+H)+.

170097-67-3, The synthetic route of 170097-67-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; F. HOFFMANN-LA ROCHE AG; HOFFMANN-LA ROCHE INC.; HERT, Jerome; HUNZIKER, Daniel; MATTEI, Patrizio; RUDOLPH, Markus; SCHMITZ, Petra; DI GIORGIO, Patrick; (81 pag.)WO2018/167113; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170097-67-3,2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid,as a common compound, the synthetic route is as follows.

Intermediate 8: 1 ,1-dimethylethyl 6-{r(5-methyl-1-{r2-(methyloxy)phenyllmethyl}-1 H-pyrazol- 3-yl)amino1carbonyl}-3,4-dihvdro-2(1 H)-isoquinolinecarboxylate; To a solution of 5-methyl-1-{[2-(methyloxy)phenyl]methyl}-1 /-/-pyrazol-3-amine (Intermediate 5) (0.1 g, 0.46 mmol) in DCM (5m L) was added 2-{[(1 ,1-dimethylethyl)oxy]carbonyl}-1 ,2,3,4- tetrahydro-6-isoquinolinecarboxylic acid (0.15 g, 0.55 mmol), HOBt (0.075 g, 0.55 mmol) and EDCI (0.105 g, 0.55 mmol), Et3N (130 muL, 0.92 mmol) and the mixture was stirred at room temperature for 48 hours. The organic phase was then washed with HCI (0.5N) and a saturated solution of NaHCO3, dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by flash column chromatography eluting with DCM to DCM/EtOAc: 80/20 to give the title compound as an oil (115 mg, 52%). LC/MS: m/z 477 (M+H)+, Rt: 3.52 min.

170097-67-3, The synthetic route of 170097-67-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2008/74833; (2008); A2;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170097-67-3,2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid,as a common compound, the synthetic route is as follows.,170097-67-3

General procedure: To a solution of corresponding acids (1.0mmol) in DCM (6mL) was added EDCI (1.5mmol), HOBt (1.5mmol), Et3N (3.0mmol) and corresponding amines (1.0mmol). The mixture was stirred at room temperature for 4h. The reaction mixture was diluted with saturated sodium bicarbonate aqueous solution (10mL) and extracted with DCM (3¡Á10mL). The combined organic layers were then dried and concentrated. The residue was purified by silica gel chromatography (dichloromethane/methanol, v/v, 90:10) to give the desired product.

The synthetic route of 170097-67-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Shao, Jingwei; Zhu, Kongkai; Du, Daohai; Zhang, Yuanyuan; Tao, Hongrui; Chen, Zhifeng; Jiang, Hualiang; Chen, Kaixian; Luo, Cheng; Duan, Wenhu; European Journal of Medicinal Chemistry; vol. 164; (2019); p. 317 – 333;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem